Shirakawa, M Shishikui Clinic
Kanamoto, Y Shishikui Clinic
Nagaoka, H Shishikui Clinic
Honda, H Minami Hospital
Low Carbohydrate Diet (LCD)
GLP-1 Receptor Agonist (GLP-1 RA)
Type 2 Diabetes Mellitus (T2DM)
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
Intestine Secretion Insulin (INCRETIN)
Recent treatment for type 2 diabetes mellitus (T2DM) has included glucagon-like peptide-1 receptor agonist (GLP-1 RA), indicating clinical efficacy for better glucose variability. Subjects were seven patients with T2DM associated with the obese tendency. Their average age was 63.8 ± 21.7 years old (5 males, 2 females) who received a new administration of GLP-1 RA (Mean ± standard deviation). For GLP-1 RA, dulaglutide (TRULICITY R, single-dose pen) was administered by subcutaneous injection 0.75 mg once a week. Basal data at 0 month revealed that body weight 76.0 ± 11.6 kg, body mass index (BMI) 29.2 ± 11.6, blood C-peptide immunoreactivity (CPR) 2.68 ± 0.49 ng/mL, respectively. After the intervention of dulaglutide, decreased value of BMI for 3 and 6-9 months was 0.78 ± 0.45 and 1.16 ± 0.85, and HbA1c for 3 and 6-9 months was 1.60 ± 1.52% and 2.01 ± 1.44%, respectively. Though these cases have various complications besides T2DM, they showed clinical effects of weight reduction and lowering blood glucose. Diabetic treatment for current cases would suggest that GLP-1 RA would be effective in various situations such as a super-aged patient, medical practice in the remote area, family care and visiting nursing.
Asploro Journal of Biomedical and Clinical Case Reports
© 2019 Shirakawa M, Kanamoto Y, Nagaoka H, et al., This is an open access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
|URL ( Publisher's Version )|
asjbccr_2_s1_38.pdf 953 KB